English version
02 Fevereiro 2009
Biotecnol and the Université de Strasbourg, INSERM, & Les Hôpitaux Universitaires de Strasbourg enter into an exclusive worldwide licensing agreement for a key oncology target

Biotecnol and the Université Louis Pasteur (ULP), together with INSERM and Les Hôpitaux Universitaires de Strasbourg (The Institutions), have announced today that they have entered into a worldwide, exclusive licensing agreement that will allow Biotecnol to develop anti-parathyroid hormone-related protein (anti-PTHrP) antagonists for treating renal cell carcinoma (RCC).

Ler mais >> Press Release


Arquivo de Notícias